nodes	percent_of_prediction	percent_of_DWPC	metapath
Bezafibrate—CYP1A1—Dacarbazine—sarcoma	0.236	0.454	CbGbCtD
Bezafibrate—CYP3A4—Thiotepa—sarcoma	0.0998	0.192	CbGbCtD
Bezafibrate—CYP2C8—Etoposide—sarcoma	0.0667	0.128	CbGbCtD
Bezafibrate—CYP3A4—Mitoxantrone—sarcoma	0.0429	0.0824	CbGbCtD
Bezafibrate—CYP3A4—Vincristine—sarcoma	0.0295	0.0567	CbGbCtD
Bezafibrate—CYP3A4—Etoposide—sarcoma	0.0271	0.052	CbGbCtD
Bezafibrate—CYP3A4—Doxorubicin—sarcoma	0.0185	0.0354	CbGbCtD
Bezafibrate—PPARG—dermis—sarcoma	0.0169	0.0758	CbGeAlD
Bezafibrate—PPARG—periosteum—sarcoma	0.014	0.0627	CbGeAlD
Bezafibrate—PPARG—leg—sarcoma	0.0112	0.05	CbGeAlD
Bezafibrate—PPARG—forelimb—sarcoma	0.0111	0.0497	CbGeAlD
Bezafibrate—PPARG—hindlimb—sarcoma	0.00997	0.0447	CbGeAlD
Bezafibrate—PPARD—mammary gland—sarcoma	0.00888	0.0398	CbGeAlD
Bezafibrate—PPARG—appendage—sarcoma	0.00855	0.0383	CbGeAlD
Bezafibrate—PPARG—Teniposide—Etoposide—sarcoma	0.00771	1	CbGdCrCtD
Bezafibrate—PPARD—hematopoietic system—sarcoma	0.00541	0.0242	CbGeAlD
Bezafibrate—PPARA—embryo—sarcoma	0.00516	0.0231	CbGeAlD
Bezafibrate—PPARG—endothelium—sarcoma	0.00516	0.0231	CbGeAlD
Bezafibrate—SLCO1B1—mammary gland—sarcoma	0.00482	0.0216	CbGeAlD
Bezafibrate—Transaminases increased—Thiotepa—sarcoma	0.00478	0.0225	CcSEcCtD
Bezafibrate—PPARA—hematopoietic system—sarcoma	0.00461	0.0207	CbGeAlD
Bezafibrate—PPARA—connective tissue—sarcoma	0.00444	0.0199	CbGeAlD
Bezafibrate—PPARG—mammary gland—sarcoma	0.00416	0.0186	CbGeAlD
Bezafibrate—Serum creatinine increased—Mitoxantrone—sarcoma	0.00408	0.0192	CcSEcCtD
Bezafibrate—PPARA—smooth muscle tissue—sarcoma	0.00406	0.0182	CbGeAlD
Bezafibrate—PPARA—skin of body—sarcoma	0.00401	0.018	CbGeAlD
Bezafibrate—PPARD—lymphoid tissue—sarcoma	0.00381	0.0171	CbGeAlD
Bezafibrate—PPARD—tendon—sarcoma	0.00358	0.016	CbGeAlD
Bezafibrate—HMGCR—myometrium—sarcoma	0.00357	0.016	CbGeAlD
Bezafibrate—PPARD—Ectoderm Differentiation—PTPRB—sarcoma	0.00345	0.0959	CbGpPWpGaD
Bezafibrate—PPARA—lymphoid tissue—sarcoma	0.00324	0.0145	CbGeAlD
Bezafibrate—HMGCR—seminal vesicle—sarcoma	0.00323	0.0145	CbGeAlD
Bezafibrate—HMGCR—hematopoietic system—sarcoma	0.00307	0.0137	CbGeAlD
Bezafibrate—PPARD—testis—sarcoma	0.00296	0.0133	CbGeAlD
Bezafibrate—HMGCR—connective tissue—sarcoma	0.00295	0.0132	CbGeAlD
Bezafibrate—SLCO1B1—hematopoietic system—sarcoma	0.00294	0.0132	CbGeAlD
Bezafibrate—PPARG—embryo—sarcoma	0.00284	0.0127	CbGeAlD
Bezafibrate—PPARD—liver—sarcoma	0.0028	0.0126	CbGeAlD
Bezafibrate—CYP2C8—mammary gland—sarcoma	0.00274	0.0123	CbGeAlD
Bezafibrate—HMGCR—smooth muscle tissue—sarcoma	0.0027	0.0121	CbGeAlD
Bezafibrate—HMGCR—skin of body—sarcoma	0.00267	0.012	CbGeAlD
Bezafibrate—PPARG—hematopoietic system—sarcoma	0.00253	0.0114	CbGeAlD
Bezafibrate—PPARA—testis—sarcoma	0.00253	0.0113	CbGeAlD
Bezafibrate—PPARG—connective tissue—sarcoma	0.00244	0.0109	CbGeAlD
Bezafibrate—Blood alkaline phosphatase increased—Thiotepa—sarcoma	0.00243	0.0114	CcSEcCtD
Bezafibrate—Myositis—Epirubicin—sarcoma	0.00239	0.0112	CcSEcCtD
Bezafibrate—PPARA—liver—sarcoma	0.00239	0.0107	CbGeAlD
Bezafibrate—HMGCR—cardiac atrium—sarcoma	0.00233	0.0104	CbGeAlD
Bezafibrate—HMGCR—uterus—sarcoma	0.00232	0.0104	CbGeAlD
Bezafibrate—PPARG—smooth muscle tissue—sarcoma	0.00223	0.01	CbGeAlD
Bezafibrate—Myositis—Doxorubicin—sarcoma	0.00221	0.0104	CcSEcCtD
Bezafibrate—PPARG—skin of body—sarcoma	0.0022	0.00988	CbGeAlD
Bezafibrate—HMGCR—lymphoid tissue—sarcoma	0.00216	0.00968	CbGeAlD
Bezafibrate—PPARD—lymph node—sarcoma	0.00215	0.00963	CbGeAlD
Bezafibrate—Phosphatase alkaline increased—Etoposide—sarcoma	0.00209	0.00983	CcSEcCtD
Bezafibrate—HMGCR—tendon—sarcoma	0.00203	0.0091	CbGeAlD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—TLE1—sarcoma	0.00203	0.0564	CbGpPWpGaD
Bezafibrate—Blood creatinine increased—Thiotepa—sarcoma	0.00198	0.00931	CcSEcCtD
Bezafibrate—Renal failure acute—Mitoxantrone—sarcoma	0.00198	0.00929	CcSEcCtD
Bezafibrate—HMGCR—bone marrow—sarcoma	0.00197	0.00881	CbGeAlD
Bezafibrate—Liver function test abnormal—Dactinomycin—sarcoma	0.00194	0.0091	CcSEcCtD
Bezafibrate—Transaminases increased—Epirubicin—sarcoma	0.00193	0.00906	CcSEcCtD
Bezafibrate—PPARG—uterus—sarcoma	0.00191	0.00858	CbGeAlD
Bezafibrate—Serum creatinine increased—Epirubicin—sarcoma	0.0019	0.00896	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Thiotepa—sarcoma	0.0019	0.00895	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00189	0.00888	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Dactinomycin—sarcoma	0.00189	0.00888	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Thiotepa—sarcoma	0.00186	0.00876	CcSEcCtD
Bezafibrate—PPARA—lymph node—sarcoma	0.00183	0.00821	CbGeAlD
Bezafibrate—PPARG—lymphoid tissue—sarcoma	0.00178	0.008	CbGeAlD
Bezafibrate—Transaminases increased—Doxorubicin—sarcoma	0.00178	0.00838	CcSEcCtD
Bezafibrate—Serum creatinine increased—Doxorubicin—sarcoma	0.00176	0.00829	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Etoposide—sarcoma	0.00174	0.0082	CcSEcCtD
Bezafibrate—Pancytopenia—Thiotepa—sarcoma	0.00173	0.00815	CcSEcCtD
Bezafibrate—Pancytopenia—Dactinomycin—sarcoma	0.00172	0.00809	CcSEcCtD
Bezafibrate—Blood creatinine increased—Mitoxantrone—sarcoma	0.00171	0.00804	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Vincristine—sarcoma	0.00169	0.00793	CcSEcCtD
Bezafibrate—HMGCR—testis—sarcoma	0.00168	0.00753	CbGeAlD
Bezafibrate—PPARG—tendon—sarcoma	0.00168	0.00752	CbGeAlD
Bezafibrate—CYP2C8—hematopoietic system—sarcoma	0.00167	0.00749	CbGeAlD
Bezafibrate—Muscular weakness—Vincristine—sarcoma	0.00165	0.00777	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Mitoxantrone—sarcoma	0.00164	0.00773	CcSEcCtD
Bezafibrate—PPARG—bone marrow—sarcoma	0.00162	0.00728	CbGeAlD
Bezafibrate—Alanine aminotransferase increased—Mitoxantrone—sarcoma	0.00161	0.00757	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Dactinomycin—sarcoma	0.0016	0.00753	CcSEcCtD
Bezafibrate—HMGCR—liver—sarcoma	0.00159	0.00712	CbGeAlD
Bezafibrate—CYP1A1—hematopoietic system—sarcoma	0.00154	0.00691	CbGeAlD
Bezafibrate—Pancytopenia—Vincristine—sarcoma	0.00154	0.00723	CcSEcCtD
Bezafibrate—SLCO1B1—liver—sarcoma	0.00152	0.00682	CbGeAlD
Bezafibrate—Pancytopenia—Mitoxantrone—sarcoma	0.0015	0.00704	CcSEcCtD
Bezafibrate—Erectile dysfunction—Vincristine—sarcoma	0.00149	0.00701	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Vincristine—sarcoma	0.00148	0.00695	CcSEcCtD
Bezafibrate—Erectile dysfunction—Mitoxantrone—sarcoma	0.00145	0.00683	CcSEcCtD
Bezafibrate—Urinary tract disorder—Thiotepa—sarcoma	0.00144	0.00679	CcSEcCtD
Bezafibrate—Pharyngitis—Dactinomycin—sarcoma	0.00144	0.00677	CcSEcCtD
Bezafibrate—Urethral disorder—Thiotepa—sarcoma	0.00143	0.00674	CcSEcCtD
Bezafibrate—PPARD—Ectoderm Differentiation—PAX3—sarcoma	0.00143	0.0398	CbGpPWpGaD
Bezafibrate—Acute coronary syndrome—Vincristine—sarcoma	0.00142	0.00669	CcSEcCtD
Bezafibrate—Myocardial infarction—Vincristine—sarcoma	0.00141	0.00665	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—PAX3—sarcoma	0.00141	0.0392	CbGpPWpGaD
Bezafibrate—PPARG—testis—sarcoma	0.00139	0.00623	CbGeAlD
Bezafibrate—Acute coronary syndrome—Mitoxantrone—sarcoma	0.00139	0.00652	CcSEcCtD
Bezafibrate—Myocardial infarction—Mitoxantrone—sarcoma	0.00138	0.00648	CcSEcCtD
Bezafibrate—Erythema multiforme—Dactinomycin—sarcoma	0.00137	0.00645	CcSEcCtD
Bezafibrate—Cramp muscle—Etoposide—sarcoma	0.00137	0.00643	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00137	0.00643	CcSEcCtD
Bezafibrate—CYP1A1—skin of body—sarcoma	0.00134	0.00601	CbGeAlD
Bezafibrate—Alanine aminotransferase increased—Etoposide—sarcoma	0.00134	0.00629	CcSEcCtD
Bezafibrate—PPARG—liver—sarcoma	0.00131	0.00589	CbGeAlD
Bezafibrate—Alopecia—Thiotepa—sarcoma	0.00129	0.00607	CcSEcCtD
Bezafibrate—Alopecia—Dactinomycin—sarcoma	0.00128	0.00603	CcSEcCtD
Bezafibrate—Urinary tract disorder—Vincristine—sarcoma	0.00128	0.00602	CcSEcCtD
Bezafibrate—Erythema—Thiotepa—sarcoma	0.00127	0.00598	CcSEcCtD
Bezafibrate—Urethral disorder—Vincristine—sarcoma	0.00127	0.00597	CcSEcCtD
Bezafibrate—Erythema—Dactinomycin—sarcoma	0.00126	0.00594	CcSEcCtD
Bezafibrate—Pharyngitis—Mitoxantrone—sarcoma	0.00125	0.00589	CcSEcCtD
Bezafibrate—Pancytopenia—Etoposide—sarcoma	0.00125	0.00586	CcSEcCtD
Bezafibrate—HMGCR—lymph node—sarcoma	0.00122	0.00546	CbGeAlD
Bezafibrate—Anaemia—Thiotepa—sarcoma	0.00118	0.00553	CcSEcCtD
Bezafibrate—Phosphatase alkaline increased—Epirubicin—sarcoma	0.00117	0.00551	CcSEcCtD
Bezafibrate—CYP1A1—cardiac atrium—sarcoma	0.00117	0.00525	CbGeAlD
Bezafibrate—Anaemia—Dactinomycin—sarcoma	0.00117	0.00549	CcSEcCtD
Bezafibrate—CYP1A1—uterus—sarcoma	0.00116	0.00522	CbGeAlD
Bezafibrate—Stevens-Johnson syndrome—Etoposide—sarcoma	0.00116	0.00545	CcSEcCtD
Bezafibrate—PPARG—Wnt Signaling Pathway Netpath—TEK—sarcoma	0.00115	0.0321	CbGpPWpGaD
Bezafibrate—Acute coronary syndrome—Etoposide—sarcoma	0.00115	0.00542	CcSEcCtD
Bezafibrate—Myocardial infarction—Etoposide—sarcoma	0.00115	0.00539	CcSEcCtD
Bezafibrate—Alopecia—Vincristine—sarcoma	0.00114	0.00539	CcSEcCtD
Bezafibrate—CYP3A4—hematopoietic system—sarcoma	0.00113	0.00507	CbGeAlD
Bezafibrate—Alopecia—Mitoxantrone—sarcoma	0.00111	0.00524	CcSEcCtD
Bezafibrate—Erythema—Mitoxantrone—sarcoma	0.0011	0.00517	CcSEcCtD
Bezafibrate—Phosphatase alkaline increased—Doxorubicin—sarcoma	0.00108	0.0051	CcSEcCtD
Bezafibrate—Myalgia—Thiotepa—sarcoma	0.00108	0.00509	CcSEcCtD
Bezafibrate—Myalgia—Dactinomycin—sarcoma	0.00107	0.00506	CcSEcCtD
Bezafibrate—Anaemia—Vincristine—sarcoma	0.00104	0.0049	CcSEcCtD
Bezafibrate—PPARA—Estrogen Receptor Pathway—JUN—sarcoma	0.00104	0.029	CbGpPWpGaD
Bezafibrate—Urinary tract disorder—Etoposide—sarcoma	0.00104	0.00488	CcSEcCtD
Bezafibrate—Infection—Thiotepa—sarcoma	0.00103	0.00485	CcSEcCtD
Bezafibrate—Urethral disorder—Etoposide—sarcoma	0.00103	0.00484	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—SMARCB1—sarcoma	0.00102	0.0285	CbGpPWpGaD
Bezafibrate—Infection—Dactinomycin—sarcoma	0.00102	0.00481	CcSEcCtD
Bezafibrate—Thrombocytopenia—Thiotepa—sarcoma	0.00102	0.00478	CcSEcCtD
Bezafibrate—Anaemia—Mitoxantrone—sarcoma	0.00102	0.00478	CcSEcCtD
Bezafibrate—Thrombocytopenia—Dactinomycin—sarcoma	0.00101	0.00474	CcSEcCtD
Bezafibrate—PPARG—lymph node—sarcoma	0.00101	0.00451	CbGeAlD
Bezafibrate—Erythema multiforme—Etoposide—sarcoma	0.000992	0.00467	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Epirubicin—sarcoma	0.000978	0.0046	CcSEcCtD
Bezafibrate—Photosensitivity—Epirubicin—sarcoma	0.000968	0.00456	CcSEcCtD
Bezafibrate—Myalgia—Vincristine—sarcoma	0.00096	0.00452	CcSEcCtD
Bezafibrate—Vascular purpura—Epirubicin—sarcoma	0.000951	0.00447	CcSEcCtD
Bezafibrate—Eczema—Epirubicin—sarcoma	0.000946	0.00445	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000946	0.00445	CcSEcCtD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—FOXO1—sarcoma	0.000939	0.0261	CbGpPWpGaD
Bezafibrate—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000939	0.00442	CcSEcCtD
Bezafibrate—Myalgia—Mitoxantrone—sarcoma	0.000935	0.0044	CcSEcCtD
Bezafibrate—Alopecia—Etoposide—sarcoma	0.000927	0.00436	CcSEcCtD
Bezafibrate—Renal failure acute—Epirubicin—sarcoma	0.000921	0.00433	CcSEcCtD
Bezafibrate—CYP2C8—testis—sarcoma	0.000916	0.0041	CbGeAlD
Bezafibrate—Infection—Vincristine—sarcoma	0.000914	0.0043	CcSEcCtD
Bezafibrate—Dyspepsia—Thiotepa—sarcoma	0.000914	0.0043	CcSEcCtD
Bezafibrate—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	0.000905	0.00426	CcSEcCtD
Bezafibrate—Thrombocytopenia—Vincristine—sarcoma	0.000901	0.00424	CcSEcCtD
Bezafibrate—Photosensitivity—Doxorubicin—sarcoma	0.000896	0.00422	CcSEcCtD
Bezafibrate—Infection—Mitoxantrone—sarcoma	0.00089	0.00419	CcSEcCtD
Bezafibrate—Pain—Thiotepa—sarcoma	0.000888	0.00418	CcSEcCtD
Bezafibrate—Constipation—Thiotepa—sarcoma	0.000888	0.00418	CcSEcCtD
Bezafibrate—Purpura—Epirubicin—sarcoma	0.000882	0.00415	CcSEcCtD
Bezafibrate—Pain—Dactinomycin—sarcoma	0.000881	0.00414	CcSEcCtD
Bezafibrate—Vascular purpura—Doxorubicin—sarcoma	0.000879	0.00414	CcSEcCtD
Bezafibrate—Muscle spasms—Etoposide—sarcoma	0.000878	0.00413	CcSEcCtD
Bezafibrate—Thrombocytopenia—Mitoxantrone—sarcoma	0.000878	0.00413	CcSEcCtD
Bezafibrate—Eczema—Doxorubicin—sarcoma	0.000875	0.00412	CcSEcCtD
Bezafibrate—CYP2C8—liver—sarcoma	0.000866	0.00388	CbGeAlD
Bezafibrate—Renal failure acute—Doxorubicin—sarcoma	0.000852	0.00401	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Thiotepa—sarcoma	0.000849	0.00399	CcSEcCtD
Bezafibrate—Anaemia—Etoposide—sarcoma	0.000844	0.00397	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Dactinomycin—sarcoma	0.000842	0.00396	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Vincristine—sarcoma	0.000839	0.00394	CcSEcCtD
Bezafibrate—Migraine—Epirubicin—sarcoma	0.000837	0.00394	CcSEcCtD
Bezafibrate—Insomnia—Vincristine—sarcoma	0.000832	0.00392	CcSEcCtD
Bezafibrate—Urticaria—Thiotepa—sarcoma	0.000825	0.00388	CcSEcCtD
Bezafibrate—Abdominal pain—Thiotepa—sarcoma	0.00082	0.00386	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000817	0.00384	CcSEcCtD
Bezafibrate—Purpura—Doxorubicin—sarcoma	0.000816	0.00384	CcSEcCtD
Bezafibrate—Abdominal pain—Dactinomycin—sarcoma	0.000814	0.00383	CcSEcCtD
Bezafibrate—CYP1A1—liver—sarcoma	0.000799	0.00358	CbGeAlD
Bezafibrate—Blood creatinine increased—Epirubicin—sarcoma	0.000797	0.00375	CcSEcCtD
Bezafibrate—Dyspepsia—Mitoxantrone—sarcoma	0.000789	0.00371	CcSEcCtD
Bezafibrate—Pain—Vincristine—sarcoma	0.000787	0.0037	CcSEcCtD
Bezafibrate—Constipation—Vincristine—sarcoma	0.000787	0.0037	CcSEcCtD
Bezafibrate—Liver function test abnormal—Epirubicin—sarcoma	0.000785	0.00369	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—MYOD1—sarcoma	0.000776	0.0216	CbGpPWpGaD
Bezafibrate—Migraine—Doxorubicin—sarcoma	0.000774	0.00364	CcSEcCtD
Bezafibrate—Pain—Mitoxantrone—sarcoma	0.000766	0.00361	CcSEcCtD
Bezafibrate—Constipation—Mitoxantrone—sarcoma	0.000766	0.00361	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000766	0.0036	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000766	0.0036	CcSEcCtD
Bezafibrate—Hypersensitivity—Thiotepa—sarcoma	0.000765	0.0036	CcSEcCtD
Bezafibrate—Hypersensitivity—Dactinomycin—sarcoma	0.000759	0.00357	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Vincristine—sarcoma	0.000753	0.00354	CcSEcCtD
Bezafibrate—Gastritis—Epirubicin—sarcoma	0.000753	0.00354	CcSEcCtD
Bezafibrate—Muscular weakness—Epirubicin—sarcoma	0.00075	0.00353	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Epirubicin—sarcoma	0.00075	0.00353	CcSEcCtD
Bezafibrate—Infection—Etoposide—sarcoma	0.000741	0.00348	CcSEcCtD
Bezafibrate—Blood creatinine increased—Doxorubicin—sarcoma	0.000737	0.00347	CcSEcCtD
Bezafibrate—Influenza—Epirubicin—sarcoma	0.000735	0.00346	CcSEcCtD
Bezafibrate—Pruritus—Thiotepa—sarcoma	0.000734	0.00345	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000733	0.00345	CcSEcCtD
Bezafibrate—Thrombocytopenia—Etoposide—sarcoma	0.00073	0.00343	CcSEcCtD
Bezafibrate—Abdominal pain—Vincristine—sarcoma	0.000728	0.00342	CcSEcCtD
Bezafibrate—Liver function test abnormal—Doxorubicin—sarcoma	0.000726	0.00342	CcSEcCtD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—MITF—sarcoma	0.000722	0.0201	CbGpPWpGaD
Bezafibrate—Urticaria—Mitoxantrone—sarcoma	0.000712	0.00335	CcSEcCtD
Bezafibrate—Diarrhoea—Thiotepa—sarcoma	0.00071	0.00334	CcSEcCtD
Bezafibrate—Abdominal pain—Mitoxantrone—sarcoma	0.000709	0.00333	CcSEcCtD
Bezafibrate—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000708	0.00333	CcSEcCtD
Bezafibrate—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000708	0.00333	CcSEcCtD
Bezafibrate—Bronchitis—Epirubicin—sarcoma	0.000707	0.00333	CcSEcCtD
Bezafibrate—Diarrhoea—Dactinomycin—sarcoma	0.000705	0.00332	CcSEcCtD
Bezafibrate—Pancytopenia—Epirubicin—sarcoma	0.000698	0.00328	CcSEcCtD
Bezafibrate—Gastritis—Doxorubicin—sarcoma	0.000696	0.00328	CcSEcCtD
Bezafibrate—Muscular weakness—Doxorubicin—sarcoma	0.000694	0.00326	CcSEcCtD
Bezafibrate—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000694	0.00326	CcSEcCtD
Bezafibrate—Dizziness—Thiotepa—sarcoma	0.000686	0.00323	CcSEcCtD
Bezafibrate—PPARG—Transcription factor regulation in adipogenesis—CREB1—sarcoma	0.000681	0.0189	CbGpPWpGaD
Bezafibrate—Influenza—Doxorubicin—sarcoma	0.00068	0.0032	CcSEcCtD
Bezafibrate—Hypersensitivity—Vincristine—sarcoma	0.000678	0.00319	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Epirubicin—sarcoma	0.000671	0.00316	CcSEcCtD
Bezafibrate—Hypersensitivity—Mitoxantrone—sarcoma	0.00066	0.00311	CcSEcCtD
Bezafibrate—Rash—Thiotepa—sarcoma	0.000654	0.00308	CcSEcCtD
Bezafibrate—Bronchitis—Doxorubicin—sarcoma	0.000654	0.00308	CcSEcCtD
Bezafibrate—Dermatitis—Thiotepa—sarcoma	0.000654	0.00308	CcSEcCtD
Bezafibrate—Headache—Thiotepa—sarcoma	0.00065	0.00306	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00065	0.00306	CcSEcCtD
Bezafibrate—Rash—Dactinomycin—sarcoma	0.00065	0.00306	CcSEcCtD
Bezafibrate—Pancytopenia—Doxorubicin—sarcoma	0.000646	0.00304	CcSEcCtD
Bezafibrate—Pain—Etoposide—sarcoma	0.000638	0.003	CcSEcCtD
Bezafibrate—Constipation—Etoposide—sarcoma	0.000638	0.003	CcSEcCtD
Bezafibrate—Diarrhoea—Vincristine—sarcoma	0.00063	0.00296	CcSEcCtD
Bezafibrate—Photosensitivity reaction—Doxorubicin—sarcoma	0.000621	0.00292	CcSEcCtD
Bezafibrate—Nausea—Thiotepa—sarcoma	0.000617	0.0029	CcSEcCtD
Bezafibrate—Diarrhoea—Mitoxantrone—sarcoma	0.000613	0.00289	CcSEcCtD
Bezafibrate—CYP1A1—lymph node—sarcoma	0.000613	0.00275	CbGeAlD
Bezafibrate—Nausea—Dactinomycin—sarcoma	0.000612	0.00288	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Etoposide—sarcoma	0.00061	0.00287	CcSEcCtD
Bezafibrate—Dizziness—Vincristine—sarcoma	0.000609	0.00286	CcSEcCtD
Bezafibrate—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000601	0.00283	CcSEcCtD
Bezafibrate—PPARA—PPAR Alpha Pathway—CCND1—sarcoma	0.000599	0.0167	CbGpPWpGaD
Bezafibrate—Urticaria—Etoposide—sarcoma	0.000592	0.00279	CcSEcCtD
Bezafibrate—Abdominal pain—Etoposide—sarcoma	0.000589	0.00277	CcSEcCtD
Bezafibrate—CYP3A4—liver—sarcoma	0.000586	0.00263	CbGeAlD
Bezafibrate—Pharyngitis—Epirubicin—sarcoma	0.000584	0.00275	CcSEcCtD
Bezafibrate—Urinary tract disorder—Epirubicin—sarcoma	0.000581	0.00273	CcSEcCtD
Bezafibrate—Rash—Vincristine—sarcoma	0.00058	0.00273	CcSEcCtD
Bezafibrate—Dermatitis—Vincristine—sarcoma	0.00058	0.00273	CcSEcCtD
Bezafibrate—Urethral disorder—Epirubicin—sarcoma	0.000577	0.00271	CcSEcCtD
Bezafibrate—Headache—Vincristine—sarcoma	0.000577	0.00271	CcSEcCtD
Bezafibrate—Rash—Mitoxantrone—sarcoma	0.000565	0.00266	CcSEcCtD
Bezafibrate—Dermatitis—Mitoxantrone—sarcoma	0.000565	0.00266	CcSEcCtD
Bezafibrate—Headache—Mitoxantrone—sarcoma	0.000562	0.00264	CcSEcCtD
Bezafibrate—Erythema multiforme—Epirubicin—sarcoma	0.000556	0.00262	CcSEcCtD
Bezafibrate—Hypersensitivity—Etoposide—sarcoma	0.000549	0.00258	CcSEcCtD
Bezafibrate—Nausea—Vincristine—sarcoma	0.000547	0.00257	CcSEcCtD
Bezafibrate—Pharyngitis—Doxorubicin—sarcoma	0.00054	0.00254	CcSEcCtD
Bezafibrate—Urinary tract disorder—Doxorubicin—sarcoma	0.000538	0.00253	CcSEcCtD
Bezafibrate—PPARA—Transcriptional activation of mitochondrial biogenesis—CREB1—sarcoma	0.000536	0.0149	CbGpPWpGaD
Bezafibrate—Urethral disorder—Doxorubicin—sarcoma	0.000534	0.00251	CcSEcCtD
Bezafibrate—Nausea—Mitoxantrone—sarcoma	0.000532	0.0025	CcSEcCtD
Bezafibrate—Pruritus—Etoposide—sarcoma	0.000527	0.00248	CcSEcCtD
Bezafibrate—Alopecia—Epirubicin—sarcoma	0.00052	0.00245	CcSEcCtD
Bezafibrate—Erythema multiforme—Doxorubicin—sarcoma	0.000515	0.00242	CcSEcCtD
Bezafibrate—Erythema—Epirubicin—sarcoma	0.000512	0.00241	CcSEcCtD
Bezafibrate—Diarrhoea—Etoposide—sarcoma	0.00051	0.0024	CcSEcCtD
Bezafibrate—Flatulence—Epirubicin—sarcoma	0.000505	0.00237	CcSEcCtD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—CCND1—sarcoma	0.000498	0.0139	CbGpPWpGaD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—JUN—sarcoma	0.000497	0.0138	CbGpPWpGaD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—CTNNB1—sarcoma	0.000493	0.0137	CbGpPWpGaD
Bezafibrate—Dizziness—Etoposide—sarcoma	0.000493	0.00232	CcSEcCtD
Bezafibrate—Muscle spasms—Epirubicin—sarcoma	0.000492	0.00232	CcSEcCtD
Bezafibrate—Alopecia—Doxorubicin—sarcoma	0.000481	0.00226	CcSEcCtD
Bezafibrate—PPARA—PPAR Alpha Pathway—MYC—sarcoma	0.00048	0.0134	CbGpPWpGaD
Bezafibrate—Erythema—Doxorubicin—sarcoma	0.000474	0.00223	CcSEcCtD
Bezafibrate—Anaemia—Epirubicin—sarcoma	0.000473	0.00223	CcSEcCtD
Bezafibrate—Rash—Etoposide—sarcoma	0.00047	0.00221	CcSEcCtD
Bezafibrate—Dermatitis—Etoposide—sarcoma	0.00047	0.00221	CcSEcCtD
Bezafibrate—Headache—Etoposide—sarcoma	0.000467	0.0022	CcSEcCtD
Bezafibrate—Flatulence—Doxorubicin—sarcoma	0.000467	0.0022	CcSEcCtD
Bezafibrate—PPARA—Mitochondrial biogenesis—CREB1—sarcoma	0.000463	0.0129	CbGpPWpGaD
Bezafibrate—PPARA—Circadian Clock—CREB1—sarcoma	0.000456	0.0127	CbGpPWpGaD
Bezafibrate—Muscle spasms—Doxorubicin—sarcoma	0.000456	0.00214	CcSEcCtD
Bezafibrate—Nausea—Etoposide—sarcoma	0.000443	0.00208	CcSEcCtD
Bezafibrate—Anaemia—Doxorubicin—sarcoma	0.000438	0.00206	CcSEcCtD
Bezafibrate—Myalgia—Epirubicin—sarcoma	0.000436	0.00205	CcSEcCtD
Bezafibrate—HMGCR—SREBP signalling—CREB1—sarcoma	0.000416	0.0116	CbGpPWpGaD
Bezafibrate—Infection—Epirubicin—sarcoma	0.000415	0.00195	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—FOXO1—sarcoma	0.000415	0.0115	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000411	0.0114	CbGpPWpGaD
Bezafibrate—Thrombocytopenia—Epirubicin—sarcoma	0.000409	0.00193	CcSEcCtD
Bezafibrate—Myalgia—Doxorubicin—sarcoma	0.000403	0.0019	CcSEcCtD
Bezafibrate—PPARD—Presenilin action in Notch and Wnt signaling—MYC—sarcoma	0.0004	0.0111	CbGpPWpGaD
Bezafibrate—Infection—Doxorubicin—sarcoma	0.000384	0.00181	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000381	0.00179	CcSEcCtD
Bezafibrate—Thrombocytopenia—Doxorubicin—sarcoma	0.000379	0.00178	CcSEcCtD
Bezafibrate—Insomnia—Epirubicin—sarcoma	0.000378	0.00178	CcSEcCtD
Bezafibrate—CYP1A1—Melatonin metabolism and effects—FOXO1—sarcoma	0.000371	0.0103	CbGpPWpGaD
Bezafibrate—CYP1A1—Estrogen Receptor Pathway—JUN—sarcoma	0.000368	0.0102	CbGpPWpGaD
Bezafibrate—Dyspepsia—Epirubicin—sarcoma	0.000368	0.00173	CcSEcCtD
Bezafibrate—Constipation—Epirubicin—sarcoma	0.000357	0.00168	CcSEcCtD
Bezafibrate—Pain—Epirubicin—sarcoma	0.000357	0.00168	CcSEcCtD
Bezafibrate—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000352	0.00166	CcSEcCtD
Bezafibrate—PPARA—Developmental Biology—MYOG—sarcoma	0.00035	0.00975	CbGpPWpGaD
Bezafibrate—Insomnia—Doxorubicin—sarcoma	0.00035	0.00165	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Epirubicin—sarcoma	0.000342	0.00161	CcSEcCtD
Bezafibrate—Dyspepsia—Doxorubicin—sarcoma	0.00034	0.0016	CcSEcCtD
Bezafibrate—Urticaria—Epirubicin—sarcoma	0.000332	0.00156	CcSEcCtD
Bezafibrate—Constipation—Doxorubicin—sarcoma	0.000331	0.00156	CcSEcCtD
Bezafibrate—Pain—Doxorubicin—sarcoma	0.000331	0.00156	CcSEcCtD
Bezafibrate—Abdominal pain—Epirubicin—sarcoma	0.00033	0.00155	CcSEcCtD
Bezafibrate—Gastrointestinal pain—Doxorubicin—sarcoma	0.000316	0.00149	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—FOXO1—sarcoma	0.000316	0.0088	CbGpPWpGaD
Bezafibrate—Hypersensitivity—Epirubicin—sarcoma	0.000308	0.00145	CcSEcCtD
Bezafibrate—Urticaria—Doxorubicin—sarcoma	0.000307	0.00145	CcSEcCtD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000307	0.00853	CbGpPWpGaD
Bezafibrate—Abdominal pain—Doxorubicin—sarcoma	0.000306	0.00144	CcSEcCtD
Bezafibrate—PPARD—Adipogenesis—CREB1—sarcoma	0.000301	0.00838	CbGpPWpGaD
Bezafibrate—Pruritus—Epirubicin—sarcoma	0.000296	0.00139	CcSEcCtD
Bezafibrate—Diarrhoea—Epirubicin—sarcoma	0.000286	0.00135	CcSEcCtD
Bezafibrate—Hypersensitivity—Doxorubicin—sarcoma	0.000285	0.00134	CcSEcCtD
Bezafibrate—Dizziness—Epirubicin—sarcoma	0.000276	0.0013	CcSEcCtD
Bezafibrate—Pruritus—Doxorubicin—sarcoma	0.000274	0.00129	CcSEcCtD
Bezafibrate—PPARG—SREBP signalling—CREB1—sarcoma	0.000273	0.00759	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—EZR—sarcoma	0.000266	0.00739	CbGpPWpGaD
Bezafibrate—Diarrhoea—Doxorubicin—sarcoma	0.000265	0.00124	CcSEcCtD
Bezafibrate—Rash—Epirubicin—sarcoma	0.000264	0.00124	CcSEcCtD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—CCND1—sarcoma	0.000263	0.00733	CbGpPWpGaD
Bezafibrate—Dermatitis—Epirubicin—sarcoma	0.000263	0.00124	CcSEcCtD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—JUN—sarcoma	0.000263	0.00731	CbGpPWpGaD
Bezafibrate—Headache—Epirubicin—sarcoma	0.000262	0.00123	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000261	0.00726	CbGpPWpGaD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—CTNNB1—sarcoma	0.000261	0.00726	CbGpPWpGaD
Bezafibrate—Dizziness—Doxorubicin—sarcoma	0.000256	0.0012	CcSEcCtD
Bezafibrate—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000254	0.00706	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MYOG—sarcoma	0.000251	0.00699	CbGpPWpGaD
Bezafibrate—Nausea—Epirubicin—sarcoma	0.000248	0.00117	CcSEcCtD
Bezafibrate—PPARG—Wnt Signaling Pathway Netpath—CCND1—sarcoma	0.000247	0.00686	CbGpPWpGaD
Bezafibrate—PPARG—Wnt Signaling Pathway Netpath—CTNNB1—sarcoma	0.000244	0.00679	CbGpPWpGaD
Bezafibrate—Rash—Doxorubicin—sarcoma	0.000244	0.00115	CcSEcCtD
Bezafibrate—Dermatitis—Doxorubicin—sarcoma	0.000244	0.00115	CcSEcCtD
Bezafibrate—Headache—Doxorubicin—sarcoma	0.000242	0.00114	CcSEcCtD
Bezafibrate—PPARD—Gene Expression—FUS—sarcoma	0.000235	0.00655	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—MDM2—sarcoma	0.000234	0.00651	CbGpPWpGaD
Bezafibrate—Nausea—Doxorubicin—sarcoma	0.00023	0.00108	CcSEcCtD
Bezafibrate—PPARA—Adipogenesis—CREB1—sarcoma	0.000229	0.00638	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—FOXO1—sarcoma	0.000227	0.00631	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000222	0.00619	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—MYOD1—sarcoma	0.000216	0.00602	CbGpPWpGaD
Bezafibrate—PPARD—Adipogenesis—CTNNB1—sarcoma	0.000215	0.00598	CbGpPWpGaD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—MYC—sarcoma	0.000211	0.00588	CbGpPWpGaD
Bezafibrate—PPARA—Organelle biogenesis and maintenance—CREB1—sarcoma	0.00021	0.00585	CbGpPWpGaD
Bezafibrate—PPARD—Ectoderm Differentiation—CTNNB1—sarcoma	0.000205	0.0057	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—CCND1—sarcoma	0.000204	0.00567	CbGpPWpGaD
Bezafibrate—PPARG—Regulation of retinoblastoma protein—JUN—sarcoma	0.000203	0.00566	CbGpPWpGaD
Bezafibrate—PPARG—Wnt Signaling Pathway Netpath—MYC—sarcoma	0.000198	0.0055	CbGpPWpGaD
Bezafibrate—HMGCR—AMPK Signaling—TP53—sarcoma	0.000198	0.0055	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—EZR—sarcoma	0.00019	0.0053	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000184	0.00512	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—FUS—sarcoma	0.000179	0.00499	CbGpPWpGaD
Bezafibrate—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—sarcoma	0.000174	0.00483	CbGpPWpGaD
Bezafibrate—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000169	0.0047	CbGpPWpGaD
Bezafibrate—PPARD—Ectoderm Differentiation—MYC—sarcoma	0.000166	0.00462	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—CREB1—sarcoma	0.000164	0.00457	CbGpPWpGaD
Bezafibrate—PPARA—Adipogenesis—CTNNB1—sarcoma	0.000164	0.00455	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—CREB1—sarcoma	0.000162	0.0045	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.00016	0.00446	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.00016	0.00445	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000159	0.00442	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—PTPRC—sarcoma	0.000157	0.00435	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MYOD1—sarcoma	0.000155	0.00432	CbGpPWpGaD
Bezafibrate—CYP1A1—Tryptophan metabolism—MDM2—sarcoma	0.000154	0.00429	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—PLCG1—sarcoma	0.000153	0.00426	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.00014	0.00389	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000138	0.00383	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000134	0.00373	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000129	0.00358	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—FUS—sarcoma	0.000128	0.00357	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000126	0.0035	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.00012	0.00334	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.00012	0.00334	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000119	0.00331	CbGpPWpGaD
Bezafibrate—PPARG—Adipogenesis—CTNNB1—sarcoma	0.000117	0.00326	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000117	0.00326	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—JUN—sarcoma	0.000116	0.00324	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—CREB1—sarcoma	0.000116	0.00323	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000116	0.00322	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—PTPRC—sarcoma	0.000112	0.00312	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—PLCG1—sarcoma	0.00011	0.00305	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—FOXO1—sarcoma	0.000109	0.00302	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000108	0.003	CbGpPWpGaD
Bezafibrate—HMGCR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000106	0.00294	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000105	0.00293	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000105	0.00293	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	9.95e-05	0.00277	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—ENO2—sarcoma	9.42e-05	0.00262	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—HBA1—sarcoma	9.36e-05	0.00261	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—KDR—sarcoma	8.99e-05	0.0025	CbGpPWpGaD
Bezafibrate—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	8.46e-05	0.00235	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—JUN—sarcoma	8.34e-05	0.00232	CbGpPWpGaD
Bezafibrate—PPARD—Metabolism—PLCG1—sarcoma	8e-05	0.00222	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—CREB1—sarcoma	7.88e-05	0.00219	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—ENO2—sarcoma	7.85e-05	0.00218	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—HBA1—sarcoma	7.8e-05	0.00217	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—FOXO1—sarcoma	7.79e-05	0.00217	CbGpPWpGaD
Bezafibrate—PPARA—Circadian rythm related genes—TP53—sarcoma	7.68e-05	0.00214	CbGpPWpGaD
Bezafibrate—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	7.58e-05	0.00211	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—MMP2—sarcoma	7.34e-05	0.00204	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—ENO2—sarcoma	7.18e-05	0.002	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—HBA1—sarcoma	7.13e-05	0.00199	CbGpPWpGaD
Bezafibrate—HMGCR—Metabolism—PLCG1—sarcoma	6.66e-05	0.00185	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—KDR—sarcoma	6.44e-05	0.00179	CbGpPWpGaD
Bezafibrate—PPARD—Generic Transcription Pathway—MYC—sarcoma	6.35e-05	0.00177	CbGpPWpGaD
Bezafibrate—PPARA—Metabolism—PLCG1—sarcoma	6.09e-05	0.0017	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—CREB1—sarcoma	5.65e-05	0.00157	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—CTNNB1—sarcoma	5.63e-05	0.00157	CbGpPWpGaD
Bezafibrate—PPARG—Circadian rythm related genes—TP53—sarcoma	5.51e-05	0.00153	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—MMP2—sarcoma	5.26e-05	0.00146	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—ENO2—sarcoma	5.15e-05	0.00143	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—HBA1—sarcoma	5.11e-05	0.00142	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—SRC—sarcoma	5.08e-05	0.00141	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—VEGFA—sarcoma	4.95e-05	0.00138	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—NRAS—sarcoma	4.89e-05	0.00136	CbGpPWpGaD
Bezafibrate—PPARA—Generic Transcription Pathway—MYC—sarcoma	4.84e-05	0.00135	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—EGFR—sarcoma	4.46e-05	0.00124	CbGpPWpGaD
Bezafibrate—PPARG—Metabolism—PLCG1—sarcoma	4.37e-05	0.00121	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—KRAS—sarcoma	4.21e-05	0.00117	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—ENO2—sarcoma	4.05e-05	0.00113	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—CTNNB1—sarcoma	4.03e-05	0.00112	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—HBA1—sarcoma	4.03e-05	0.00112	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—SRC—sarcoma	3.64e-05	0.00101	CbGpPWpGaD
Bezafibrate—PPARA—Developmental Biology—HRAS—sarcoma	3.58e-05	0.000996	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—VEGFA—sarcoma	3.55e-05	0.000988	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—NRAS—sarcoma	3.51e-05	0.000975	CbGpPWpGaD
Bezafibrate—PPARG—Generic Transcription Pathway—MYC—sarcoma	3.47e-05	0.000965	CbGpPWpGaD
Bezafibrate—SLCO1B1—Metabolism—PLCG1—sarcoma	3.44e-05	0.000957	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—EGFR—sarcoma	3.19e-05	0.000889	CbGpPWpGaD
Bezafibrate—PPARD—Gene Expression—MYC—sarcoma	3.06e-05	0.000851	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—KRAS—sarcoma	3.02e-05	0.00084	CbGpPWpGaD
Bezafibrate—PPARG—Developmental Biology—HRAS—sarcoma	2.56e-05	0.000714	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—ENO2—sarcoma	2.54e-05	0.000707	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—HBA1—sarcoma	2.52e-05	0.000702	CbGpPWpGaD
Bezafibrate—PPARA—Gene Expression—MYC—sarcoma	2.33e-05	0.000649	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—ENO2—sarcoma	2.33e-05	0.000648	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—HBA1—sarcoma	2.31e-05	0.000644	CbGpPWpGaD
Bezafibrate—CYP1A1—Metabolism—PLCG1—sarcoma	2.15e-05	0.0006	CbGpPWpGaD
Bezafibrate—CYP2C8—Metabolism—PLCG1—sarcoma	1.98e-05	0.00055	CbGpPWpGaD
Bezafibrate—PPARG—Gene Expression—MYC—sarcoma	1.67e-05	0.000465	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—ENO2—sarcoma	1.25e-05	0.000348	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—HBA1—sarcoma	1.24e-05	0.000346	CbGpPWpGaD
Bezafibrate—CYP3A4—Metabolism—PLCG1—sarcoma	1.06e-05	0.000295	CbGpPWpGaD
